Paris (France), San Francisco (USA), February 8, 2022, at 7:00 am CET – Lauxera Capital Partners announced today the final closing of its first fund, Lauxera Growth I, at more than €260 million (approximately $300 million), making it one of the leading European funds dedicated to financing innovative HealthTech companies.

Launched in January 2021, Lauxera Growth I exceeded its initial fundraising target of €150 million and its initial hard cap of €200 million. The fund’s upsized raise reflects the strength and depth of the investment opportunities in fast-growing European HealthTech companies providing innovative solutions.

Lauxera Growth I makes minority Growth and majority Growth Buyout investments leveraging the operational and strategic experience of its team to help founders and managers drive international commercialization, particularly in the U.S. market. Lauxera Capital invests up to €20-40 million in each company and more with the support of its limited partners.

Led by a team of former Healthtech executives and experienced investors, Lauxera Growth I achieved a first closing in January 2021 of nearly €100 million. The closing was made possible with the strategic support of investors such as Covea, Candriam and Bpifrance, the French national investment bank, which invested in equity and through its Growth fund of fund on behalf of private insurers and the French public financial institution Caisse des Dépôts. Major European family offices also participated such as Tethys, Compagnie Nationale à Portefeuille (CNP), Financière Dassault, and Italmobiliare. Lauxera Capital Partners’ targeted strategy, the international expertise of its team, and the first investments made by the fund led to additional commitments from other leading investors such as the European Investment Fund (EIF), the Biotech Health Acceleration fund (FABS) handled on behalf of the French government by Bpifrance as part of the Programme d’investissements d’avenir, insurance leaders Matmut and Harmonie Mutuelle (Vyv Group), and Swen Capital Partners.

Pierre Moustial, Chairman and co-founder of Lauxera Capital Partners said: “After a first closing in January 2021 of nearly €100 million, we are very proud to have exceeded all our initial targets in less than a year, closing our Lauxera Growth I fund at over €260 million. Its size and the quality of its limited partners allow us to operate at the same level as the largest American specialist funds financing HealthTech innovators with global ambitions. We can accelerate the international growth of our portfolio companies and transform them into multinational champions in HealthTech. Over the past year, we have invested close to 25% of the 2 fund’s final size in five companies, playing active governance and advisory roles to accelerate their growth.”

Among its first five investments, Lauxera Growth I acted as lead or co-lead investor in the latest financing rounds of Reapplix (Denmark), LUMICKS (Netherlands), Caresyntax (Germany & USA), and Lifen (France), and led the acquisition of a majority stake in Groupe PSIH (France).

Dr. Samuel Levy and Alex Slack, co-founders of Lauxera Capital Partners, added: “From the outset, our vision has been to position our fund as a key player in supporting the scale-up of European HealthTech companies. As the critical challenge for these companies is to quickly penetrate the US market, our network, our regulatory and commercial skills, and our transatlantic positioning naturally make us the ideal partner. Europe has an unparalleled wealth of Healthtech innovations and an array of great medical technology companies in Healthtech software, medical devices, research tools, digital health, and biomanufacturing that can radically improve the efficiency of our Healthtech systems while improving outcomes for patients.”

Lauxera Growth I has been awarded the label “Plan de Financement de la Tech” (“Plan Tibi”) by the French Government as part of its charter with participating institutional investors aimed at enhancing financing opportunities for technology companies.

Philippe Tibi, President of the Executive Committee and the Technical Committees of the “Tech Financing Plan” project within the French Ministry for the Economy, Finance and Recovery, concluded: “Our initiative has two strategic objectives: to significantly strengthen the human technology ecosystem in France and to increase the resources of ambitious growth/late-stage investment funds in their areas of excellence, including first time funds. I am therefore delighted with Lauxera’s success with LPs and wish its teams the greatest success in developing leading HealthTech companies.”